# Octreotide

## Sandostatin inj 0.1mg/1mL

##### 臨採

| 標題       | 說明                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 藥品代碼   | ISAN1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| 適應症     | Symptomatic control & reduction of growth hormone & somatomedin C plasma levels in acromegaly; relief of symptoms associated with gastroenteropancreatic endocrine (GEP) tumors & carcinoid tumors including VIPomas, glucagonomas, gastrinomas/Zollinger-Ellison syndrome, insulinomas, GRFomas. Prevention of complications following pancreatic surgery. Bleeding gastro-oesophageal varices.                                                                                                                           |
| 用法用量   | Acromegaly: Initially IM 0.05-0.1mg every 8-12 hour, could increased up to 1.5mg. Functional gastrointestinal pancreatic endocrine tumor: Initially IM 0.05mg 1-2 times per day, followed by 0.1-0.2mg three times per day. Complications after pancreatic surgery: IM 0.1mg three times per day for 7 days. Bleeding esophageal varices: diluted in normal saline and IV infusion 25mcg per hour for 5 days.                                                                                                              |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 禁忌       | Known hypersensitivity to octreotide or one of the excipients (see Description) of Sandostatin                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 副作用     | Anorexia, nausea, vomiting, crampy abdominal pain, abdominal bloating, flatulence, loose stools, steatorrhea, rarely progressive abdominal distension, severe epigastric pain, gallstones. Dermatologic: Injection site pain Endocrine metabolic: Hyperglycemia (1.5% to 16%), Hypoglycemia (1.5% to 3%), Hypothyroidism Gastrointestinal: Abdominal discomfort, Cholelithiasis (22% to 33% ), Constipation, Diarrhea, Flatulence, Nausea, Pancreatitis Hepatic: Disorder of biliary tract Neurologic: Dizziness, Headache |
| 孕期建議   | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 哺乳期建議 | No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

